Roche's Actemra nabs 'breakthrough' tag for new use; Novartis rolls out new Cosentyx data in ankylosing spondylitis;

> Roche ($RHHBY) won the FDA's coveted "breakthrough" designation for a new use for its anti-inflammatory drug Actemra, in patients with systemic sclerosis. Release

> Novartis ($NVS) touted one-year data from its MEASURE 2 study showing that 74% of ankylosing spondylitis patients saw significant, sustained improvement with Cosentyx therapy. Release

> The National Institute for Health and Care Excellence turned down Celgene's ($CELG) psoriasis med Otezla, in contrast to the Scottish Medicines Consortium's decision in favor of the drug. Report

> Life sciences sales specialist Aktana rolled out a new product connecting its decision-making support solution to Veeva Systems' new CRM software. Release (PDF)

And Finally... Johnson & Johnson's ($JNJ) Tylenol brand ID'd Canada's most sleepless cities in a survey to help sell its sleep aids. Report


Suggested Articles

Breztri Aerosphere, AZ's three-in-one COPD inhaler, just won its first global nod to rival GlaxoSmithKline's Trelegy Ellipta.

Could an overhauled marketing campaign featuring new pain data help sales of Ironwood and Allergan’s struggling GI drug Linzess?

Forget the charts and graphs. Lead with your heart. That’s the message from Attila Cansun, a chief marketing officer at the newly rebranded P&G Health.